With the CE Mark approval, Cothera will market the Vpulse system in the EU and other countries that recognize or require this approval.

Cothera claims that the Vpulse system is unique in the marketplace in that it combines intermittent pneumatic compression for deep vein thrombosis prevention, dynamic compression therapy, and cold therapy into a convenient, single user, post-surgical rehabilitation device for hospital, clinic and home environments.

Cothera general manager Howard Edelman said that the Vpulse system combines DVT prevention and post orthopedic procedure rehabilitation and places these effective therapies and significant convenience in the hands of the patients.

"This designation recognizes Cothera’s continued commitment to provide our customers with outstanding, high quality products and puts us on a path to increase international sales," Edelman added.

According to Cothera, the Vpulse System is available to help hospitals control readmission related costs, while supporting clinician treatment plans.